Cargando…

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer

The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cattrini, Carlo, Castro, Elena, Lozano, Rebeca, Zanardi, Elisa, Rubagotti, Alessandra, Boccardo, Francesco, Olmos, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770296/ https://www.ncbi.nlm.nih.gov/pubmed/31547436 http://dx.doi.org/10.3390/cancers11091355

Ejemplares similares

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
por: Cattrini, Carlo, et al.
Publicado: (2019)

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
por: Messina, Carlo, et al.
Publicado: (2020)

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes
por: Cavo, Alessia, et al.
Publicado: (2018)

To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone
por: Zanardi, Elisa, et al.
Publicado: (2019)

Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
por: Lozano, Rebeca, et al.
Publicado: (2020)

Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients
por: Cattrini, Carlo, et al.
Publicado: (2023)

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients
por: Sigurdson, Samantha S., et al.
Publicado: (2020)

Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review
por: Ong, Sean, et al.
Publicado: (2021)

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2021)

Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death
por: Nuzzo, Pier Vitale, et al.
Publicado: (2012)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa)
por: Nuzzo, Pier Vitale, et al.
Publicado: (2015)

A hnRNP K–AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer
por: Capaia, Matteo, et al.
Publicado: (2018)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
por: Hall, Mary E, et al.
Publicado: (2020)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

BRCA2 and Other DDR Genes in Prostate Cancer
por: Nombela, Paz, et al.
Publicado: (2019)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome
por: Nuzzo, P. V., et al.
Publicado: (2016)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
por: Garg, Manish, et al.
Publicado: (2013)

Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer
por: Barboro, P, et al.
Publicado: (2009)

Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches
por: Posdzich, Philip, et al.
Publicado: (2023)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?
por: Bišof, Vesna
Publicado: (2019)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021)

Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2022)

SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
por: Omrčen, Tomislav
Publicado: (2022)

Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
por: Chen, Kenneth, et al.
Publicado: (2022)

Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy
por: Verzoni, Elena, et al.
Publicado: (2022)

Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
por: Preisser, Felix, et al.
Publicado: (2021)

Chronic prostatitis: current treatment options
por: Pirola, Giacomo Maria, et al.
Publicado: (2019)

Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume
por: Alhanafy, Alshimaa Mahmoud, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_iaej0jler3nebue32d3dcfujen